Tab. II.
Distribution of antimicrobial agents (ATC* 4th levels) by main indication for use, ECDC pilot point prevalence survey, 2011 (n = 223 antimicrobial agents).
| All indication | Treatment | Surgical prophylaxis | Medical prophylaxis | |
|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | |
| Antimicrobial agents, total | 223 (100) | 113 (100) | 73 (100) | 37 (100) |
| Top antimicrobial agents at ATC 4th level | ||||
| Fluoroquinolones (J01MA) | 56 (25.1) | 34 (30.1) | 12 (16.4) | 10 (27.0) |
| Third-generation cephalosporins (J01DD) | 55 (24.6) | 12 (10.6) | 35 (47.9) | 8 (21.6) |
| First-generation cephalosporins (J01DB) | 1 (0.4) | – | 1 (1.4) | – |
| Nitroimidazole derivates (P01AB) | 27 (12.1) | 11 (9.7) | 10 (13.7) | 6 (16.2) |
| Combinations of penicillins, incl.β-lactamase inhibitors (J01CR) | 18 (8.1) | 11 (9.7) | 4 (5.4) | 3 (8.1) |
| Combination of sulfonamides and trimethoprim (J01CA) | 10 (4.4) | 4 (3.5) | 2 (2.7) | 4 (10.8) |
| Macrolides (J01FA) | 9 (4.0) | 6 (5.3) | – | 3 (8.1) |
| Glycopeptide antibacterials (J01XA) | 9 (4.0) | 9 (7.9) | – | – |
| Aminoglycosides (J01GB) | 8 (3.6) | 4 (3.5) | 4 (5.4) | – |
| Penicillins, extended spectrum without anti-pseudomonal activity (J01CA) | 8 (3.6) | 6 (5.3) | 2 (2.7) | – |
| Carbapenems (J01DH) | 7 (3.1) | 6 (5.3) | 1 (1.4) | – |
| Antidiarrheals, intestinal anti-inflammatory/anti-infective agents (A07AA) | 5 (2.2) | 3 (2.6) | – | 2 (5.4) |
| Triazole derivates (J02AC) | 3 (1.3) | 3 (2.6) | – | – |
| Antimycobacterials for treatment of tuberculosis (J04A) | 2 (0.8) | 2 (1.7) | – | – |
| Tetracyclines (J01AA) | 1 (0.4) | 1 (0.8) | – | – |
| Other antibacterials (J01XX) | 3 (1.3) | 1 (0.8) | 1 (1.4) | 1 (2.7) |
*
Anatomical Therapeutic Chemical